SSKN STRATA Skin Sciences, Inc.

OTC Surgical & Medical Instruments & Apparatus DE CIK: 0001051514
AI RATING
STRONG_SELL
90% Confidence

Investment Thesis

STRATA is in severe financial distress with persistent operating losses (-15.3% margin), negative free cash flow (-$4.3M), and minimal equity ($2.9M) supporting extreme leverage (5.28x debt-to-equity). Declining revenue (-8.5% YoY), liquidity deterioration (0.58x current ratio), and inability to service debt (negative interest coverage) present acute solvency risk.

Strengths

  • + Gross margin of 58.3% indicates reasonable product economics and pricing power
  • + Cash position of $7.9M provides near-term operational buffer
  • + Net loss improved 37.9% YoY, indicating some operational improvement trajectory

Risks

  • ! Persistent unprofitability: -$6.3M net income, -15.3% operating margin, -20.4% net margin
  • ! Extreme leverage with minimal equity cushion: $15.3M debt on $2.9M equity (5.28x debt-to-equity ratio)
  • ! Negative free cash flow generation (-$4.3M) indicates cash burn despite gross profitability
  • ! Deteriorating liquidity: current ratio 0.58x, quick ratio 0.48x (both below 1.0 threshold)
  • ! Negative interest coverage (-9.0x) and inability to cover debt service from operations
  • ! Declining revenue (-8.5% YoY) undermines recovery narrative
  • ! Zero insider buying activity in 90 days suggests confidence deficit

Key Metrics to Watch

Financial Metrics

Revenue
30.7M
Net Income
-6.3M
EPS (Diluted)
$-1.35
Free Cash Flow
-4.3M
Total Assets
30.5M
Cash
7.9M

Profitability Ratios

Gross Margin 58.3%
Operating Margin -15.3%
Net Margin -20.4%
ROE -215.3%
ROA -20.5%
FCF Margin -13.9%

Balance Sheet & Liquidity

Current Ratio
0.58x
Quick Ratio
0.48x
Debt/Equity
5.28x
Debt/Assets
90.5%
Interest Coverage
-8.97x
Long-term Debt
15.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-16T15:27:21.797907 | Data as of: 2025-12-31 | Powered by Claude AI